52-week high alert: This pharmaceutical company stock surges on getting USFDA’s approval for new drug!

Ashwin Urkude
/ Categories: Trending, Mindshare
52-week high alert: This pharmaceutical company stock surges on getting USFDA’s approval for new drug!

This drug had estimated annual sales of USD 262 million in the US.

Lupin Ltd has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Obeticholic Acid Tablets, 5 mg and 10 mg, a generic equivalent of Ocaliva Tablets, 5 mg and 10 mg, of Intercept Pharmaceuticals, Inc. This product will be manufactured at Lupin’s Nagpur facility in India. As per IQVIA MAT March 2023 sales data, Obeticholic Acid tablets had estimated annual sales of USD 262 million in the US.

Lupin is an innovation-led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

 

DSIJ offers a service 'Upstream' with recommendations for contrarian stocks based on research and analysis to help subscribers make informed investment decisions. If this interests you, then do download the service details pdf here 

 

Lupin is currently trading at Rs 814.05, up by 9.50 points or 1.18 per cent from its previous closing of Rs 804.55 on the BSE. The scrip opened at Rs 800.05 and has touched a high and low of Rs 816.90 and Rs 800.05 respectively. So far 20,727 shares were traded on the counter.

The BSE group 'A' stock of face value of Rs 2 has touched a 52-week high of Rs 816.90 on June 1, 2023, and a 52-week low of Rs 592.55 on Jun 17, 2022.

Rate this article:
3.8

Leave a comment

Add comment

DSIJ MINDSHARE

Mkt Commentary29-Sep, 2023

Penny Stocks1-Oct, 2023

Mindshare1-Oct, 2023

Mindshare1-Oct, 2023

Mindshare1-Oct, 2023

Knowledge

General30-Sep, 2023

General26-Sep, 2023

Technical25-Sep, 2023

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Investment in securities market are subject to market risks.Read all the related documents carefully before investing.
Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.